Novartis's pricing might be tested with costly eye therapy
ZURICH (Reuters) – Novartis’s price-setting muscle is about to be tested after it won European Union approval for a blindness-fighting gene therapy whose $ 850,000 list cost in the United States has been labeled too expensive by some groups. FILE PHOTO: A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013.… Read More »